Daiichi Sankyo, Merck
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study,
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival compared to chemotherapy.
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer. The drug helped patients live significantly longer without their cancer progressing,
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs called antibody-drug conjugates (ADC),
pharmaphorum10h
Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
ジャパンタイムズ2d
Daiichi wants to go it alone in search for targeted cancer drugs
The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...
FiercePharma1d
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours
Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of ...
devdiscourse1d
Recent Health Developments: Affordable Medicines, Breakthrough Devices, and Global Campaigns
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
FiercePharma6d
ESMO: AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases
Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
In the trial, most interstitial lung disease events were observed to be low grade, with two grade 5 ILD events being reported ...